Using proprietary assays, Cognition Therapeutics Inc. has discovered small-molecule, highly brain-penetrable drugs that block soluble toxic amyloid beta oligomers in their reactive form, rather than target amyloid beta plaque or expression of the monomer building blocks.
2403 Sidney Street
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
